Does Dr. ROBERT GOTTLIEB have financial conflicts of interest?

Dr. ROBERT GOTTLIEB (M.D. PH.D.) has received a total of $646,857 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $617,272 in personal promotional payouts (consulting, meals, travel) and $29,585 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ROBERT GOTTLIEB?

According to CMS Open Payments data, Dr. ROBERT GOTTLIEB received funding from ALNYLAM PHARMACEUTICALS ($308,481), GILEAD SCIENCES ($203,299), and F. HOFFMANN-LA ROCHE AG ($39,555).

Does Dr. ROBERT GOTTLIEB receive research grants or speaking fees?

Dr. ROBERT GOTTLIEB has received $617,272 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $29,585 in clinical research grants.

DR. ROBERT GOTTLIEB

M.D. PH.D.Real-Time Hydrated

Specialty: Internal Medicine, Advanced Heart Failure and Transplant Cardiology

Practice Location: DALLAS, TX 75246

NPI Number: 1386855922

LIFETIME INDUSTRY VALUE

$646,857

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. GOTTLIEB is a verified Internal Medicine, Advanced Heart Failure and Transplant Cardiology practitioner based in DALLAS, TX.

Between 2021 and 2025, Dr. GOTTLIEB had an overall industry promotional and research financial footprint of $646,857 as recorded in the federal CMS Open Payments database.

$617,272 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$29,585 was allocated to sponsored clinical trials and medical research activities.

Dr. GOTTLIEB's primary funding source is ALNYLAM PHARMACEUTICALS, which accounts for $308,481 (representing 47.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ALNYLAM PHARMACEUTICALS

Rank 1

$308,481

47.7%

GILEAD SCIENCES

Rank 2

$203,299

31.4%

F. HOFFMANN-LA ROCHE AG

Rank 3

$39,555

6.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.